Major U.S. drugmaker Pfizer Inc. on Friday filed for a fast-track approval in Japan of its COVID-19 vaccine, marking the first such application made in the nation, with industry sources saying the formal approval could come within months amid the ongoing novel coronavirus pandemic.
The U.K. and the U.S. have already started this month administering the firm's mRNA vaccine, developed jointly with Germany’s BioNTech SE, and this week Singapore became the first Asian country to grant approval for its use.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see this support page.
We humbly apologize for the inconvenience.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
SUBSCRIBE NOW
PHOTO GALLERY (CLICK TO ENLARGE)
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.